TY - JOUR
T1 - Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma
T2 - A nationwide case series of 35 patients in The Netherlands
AU - Boon, Eline
AU - van Boxtel, Wim
AU - Buter, Jan
AU - Baatenburg de Jong, Robert J.
AU - van Es, Robert J.J.
AU - Bel, Miranda
AU - Fiets, Edward
AU - Oosting, Sjoukje F.
AU - Slingerland, Marije
AU - Hoeben, Ann
AU - Tesselaar, Margot E.T.
AU - Jonker, Marianne A.
AU - Flucke, Uta E.
AU - van der Graaf, Winette T.A.
AU - van Herpen, Carla M.L.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Background: Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor-positive. Only limited data are available on androgen deprivation therapy (ADT). Methods: Patients with advanced androgen receptor-positive salivary duct carcinoma treated with first-line ADT were retrospectively evaluated for clinical benefit (ie, partial response [PR] and stable disease, progression-free survival [PFS] and overall survival [OS]). The OS was compared with patients with advanced salivary duct carcinoma who received best supportive care. Results: Thirty-four of 35 patients who were ADT-treated were evaluable: 6 patients had a PR (18%) and 11 had stable disease (32%) leading to a clinical benefit ratio of 50%. The median PFS for the ADT-treated patients was 4 months and the median duration of clinical benefit was 11 months. The median OS was 17 months versus 5 months in 43 patients receiving best supportive care (P=.02). Conclusion: We recommend ADT in advanced androgen receptor-positive salivary duct carcinoma given its response and clinical benefit.
AB - Background: Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor-positive. Only limited data are available on androgen deprivation therapy (ADT). Methods: Patients with advanced androgen receptor-positive salivary duct carcinoma treated with first-line ADT were retrospectively evaluated for clinical benefit (ie, partial response [PR] and stable disease, progression-free survival [PFS] and overall survival [OS]). The OS was compared with patients with advanced salivary duct carcinoma who received best supportive care. Results: Thirty-four of 35 patients who were ADT-treated were evaluable: 6 patients had a PR (18%) and 11 had stable disease (32%) leading to a clinical benefit ratio of 50%. The median PFS for the ADT-treated patients was 4 months and the median duration of clinical benefit was 11 months. The median OS was 17 months versus 5 months in 43 patients receiving best supportive care (P=.02). Conclusion: We recommend ADT in advanced androgen receptor-positive salivary duct carcinoma given its response and clinical benefit.
KW - Androgen deprivation therapy
KW - Androgen receptors
KW - Antineoplastic agents
KW - Hormonal
KW - Salivary duct carcinoma
KW - Salivary gland neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85038838983&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/hed.25035
DO - https://doi.org/10.1002/hed.25035
M3 - Article
C2 - 29272069
SN - 1043-3074
VL - 40
SP - 605
EP - 613
JO - Head and Neck
JF - Head and Neck
IS - 3
ER -